Abstract
Background
A dysfunctional osteoclast activity is often the cause of bone destructive diseases, such as osteoporosis, periodontitis, erosive arthritis, and cancer. The NFκB ligand (RANKL) has been identified as a major mediator of bone resorption. Agents that suppress RANKL signaling have the potential to inhibit bone resorption or osteoclastogenesis. The present study aimed to determine the effect of a pterostilbene derivative (PTERC-T) for suppressing RANKL or tumor cells-induced osteoclastogenesis in RAW264.7 murine macrophages.
Methods
Cytotoxicity was measured by MTT assay and inhibitory effect on osteoclastogenesis was analyzed by counting the number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells and measuring the expression levels of the osteoclast-specific genes. The reactive oxygen species (ROS) generation was detected by FACS. Further, signaling pathways were analyzed by immunofluorescence and immunoblot analyses.
Results
PTERC-T suppressed the differentiation of monocytes to osteoclasts in a dose and time-dependent manner. The expression of osteoclast marker genes like TRAP, cathepsin K (CTSK), matrix metalloproteinase 9 (MMP9) and transcription factors c-Fos, and nuclear factor of activated T cells cytoplasmic 1 (NFATc1) were also diminished by PTERC-T. PTERC-T scavenged intracellular ROS generation within osteoclast precursors during RANKL-stimulated osteoclastogenesis. Mechanistically, PTERC-T abrogated the phosphorylation of MAPKs (ERK and JNK) and inhibited RANKL-induced activation of NFκB by suppressing IκBα phosphorylation and preventing NFκB/p65 nuclear translocation.
Conclusions
This study thus identifies PTERC-T as an inhibitor of osteoclast formation and provides evidence for its role in preventing osteoporosis and other bone related disorders. However, further studies are needed to establish its efficacy in vivo.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Novack DV, Teitelbaum SL. The osteoclast: friend or foe. Annu Rev Pathol 2008;3:457–84.
Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289(5484):1508–14.
Baud’huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, et al. Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev 2013;24(5):401–9.
Sigl V, Penninger JM. RANKL/RANK – from bone physiology to breast cancer. Cytokine Growth Factor Rev 2014;25(2):205–14.
Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3(6):889–901.
Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12(1):17–25.
Borriello A, Bencivenga D, Caldarelli I, Tramontano A, Borgia A, Pirozzi AV, et al. Resveratrol and cancer treatment: is hormesis a yet unsolved matter? Curr Pharm Des 2013;19(30):5384–93.
Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaissé JM. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005;65(21):9943–52.
Lee YS, Kim YS, Lee SY, Kim GH, Kim BJ, Lee SH, et al. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 2010;47(5):926–37.
He X, Andersson G, Lindgren U, Li Y. Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun 2010;401(3):356–62.
Brisdelli F, D’Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 2009;10(6):530–46.
Lin HS, Yue BD, Ho PC. Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomed Chromatogr 2009;23(12):1308–15.
Nikhil K, Sharan S, Chakraborty A, Bodipati N, Krishna Peddinti R, Roy P. Role of isothiocyanate conjugate of pterostilbene on the inhibition of MCF-7 cell proliferation and tumor growth in Ehrlich ascitic cell induced tumor bearing mice. Exp Cell Res 2014;320(2):311–28.
Nikhil K, Sharan S, Chakraborty A, Roy P. Pterostilbene–isothiocyanate conjugate suppresses growth of prostate cancer cells irrespective of androgen receptor status. PLOS ONE 2014;9(4):e93335.
Nikhil K, Sharan S, Singh AK, Chakraborty A, Roy P. Anticancer activities of pterostilbene–isothiocyanate conjugate in breast cancer cells: involvement of PPAR. PLOS ONE 2014;9(8):e104592.
Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K, Tsuda E, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 2000;267(2):632–7.
Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005;106(3):852–9.
Ha H, Kwak HB, Lee SW, Jin HM, Kim HM, Kim HH, et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 2004;301(2):119–27.
Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24(5A):2783–840.
Teitelbaum SL. RANKing c-Jun in osteoclast development. J Clin Invest 2004;114(4):463–5.
Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007;40(2):251–64.
Kim KN, Heo SJ, Yoon WJ, Kang SM, Ahn G, Yi TH, et al. Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW264.7 macrophages. Eur J Pharmacol 2010;649(1–3):369–75.
Stevenson DA, Schwarz EL, Carey JC, Viskochil DH, Hanson H, Bauer S, et al. Bone resorption in syndromes of the Ras/MAPK pathway. Clin Genet 2011;80(6):566–73.
Nikhil K, Sharan S, Palla SR, Sondhi SM, Peddinti RK, Roy P. Understanding the mode of action of a pterostilbene derivative as anti-inflammatory agent. Int Immunopharmacol 2015;28:10–21.
Zhou H, Shang L, Li X, Zhang X, Gao G, Guo C, et al. Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells. Exp Cell Res 2009;315(17):2953–62.
Dai Z, Li Y, Quarles LD, Song T, Pan W, Zhou H, et al. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 2007;14(12):806–14.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nikhil, K., Sharan, S. & Roy, P. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells. Pharmacol. Rep 67, 1264–1272 (2015). https://doi.org/10.1016/j.pharep.2015.05.009
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2015.05.009